To develop a vaccine to inhale from the nose to verify the effect Kitasato University group July 24 5:29

Vaccines prevent infection by the action of antibodies, but in the case of new coronavirus, it has been reported that the antibodies in the blood started to decrease after a while even after infection, and it is pointed out that there are challenges in vaccine development. A group at Kitasato University is developing a new vaccine that prevents infection by inhaling from the nose by making antibodies at the back of the nose, which is the entrance of the virus, and will confirm the effect in animal experiments in the near future.

It is unclear whether antibodies will be maintained in the new coronavirus, such as a study published by China that the antibodies in the blood formed after infection began to decline in the months to come, and there is a problem in vaccine development. It is pointed out that there is.

To solve these problems, the research group of Professor Kazuhiko Katayama at Kitasato University is developing a new type of vaccine that inhales through the nose to make antibodies to the mucous membrane of the nose, which is first infected by the virus.

This vaccine injects a protein that causes an immune response using extremely small needle-shaped molecules that dissolve in cells called "molecular needles", and it is locally inhaled into the mucous membrane of the nose by inhalation. It creates antibodies to prevent infection.

The research group says that it is more effective than making antibodies in the blood by injection, and vaccination is easy, so it is easy to cope with the decrease in antibodies.

Professor Katayama said, "The new coronavirus has individual differences in how antibodies can be made, and I do not know how long it will be maintained. I would like to develop it to deliver peace of mind." , I want to confirm the effect.